Selected for VERZENIO LD Network

October 16, 2017

Selected for VERZENIO LD Network

Onco360 has been selected to participate in the limited distribution network for Eli Lilly’s product, VERZENIO™ (abemaciclib), a twice daily oral cyclin-dependent kinase (CDK) 4/6 inhibitor approved by the U.S. Food and Drug Administration (FDA). VERZENIO is used in combination with fulvestrant to treat women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer, or breast cancer that has spread to other parts of the body (metastatic), whose disease has progressed after receiving hormonal therapy.

VERZENIO is also approved as a monotherapy to treat adults with HR+, HER2- advanced breast cancer, or metastatic breast cancer whose disease has progressed after receiving hormonal therapy and chemotherapy in the metastatic setting. Full Prescribing information.

“VERZENIO is a highly anticipated product that provides another therapy option for patients battling advanced breast cancer, said Onco360 President and CEO Paul Jardina. The worlds top biopharmaceutical companies, including Eli Lilly, continue to leverage Onco360 for our patient-centric approach to cancer care when choosing a pharmacy network to distribute their pioneering new treatments in oncology. We are pleased to have been selected to join the limited distribution network for VERZENIO and look forward to providing outstanding care to patients who have a critical need for this therapy”.